Experimental research shows nanoencapsulated scopoletin induces dose-dependent cell death in HT-29 colorectal cancer, highlighting its therapeutic promise.
In the sphere of medical research, nanoencapsulated polymeric drugs in biological circumstances are an intriguing issue for therapeutical diagnosis. The nanoprecipitation approach was employed in this study to synthesis the nanoencapsulated polymeric scopoletin (NEP‐Sc) and tested its effect against the HT‐29 cell line (human colorectal adenocarcinoma cells). Further, the synthesized NEP‐Sc was then characterized by ultra‐visible spectroscopy (UV–Vis), Fourier transform infrared spectroscopy (FTIR), X‐ray diffraction (XRD), field emission scanning electron microscopy (FE‐SEM) with energy dispersive X‐ray analysis (EDAX), and dynamic light scattering (DLS) analysis. All the analysis confirmed the effective synthesis of NEP‐Sc. The synthesized NEP‐Sc was validated as anticancer drug through the conventional MTT assay, neutral red uptake assay, apoptosis assay using AO/EB and lactate dehydrogenase assay and trypan blue assay against HT‐29 cells. The docking studies of scopoletin with multiple genes were also carried out using the PyRx—virtual screening tool. The findings indicated that increase in concentration of NEP‐Sc exhibited dose dependent action of cell death against the HT‐29 colon cancer cells. To summarize, the observed results of anticancer and computational modeling studies underscores the therapeutic potential of NEP‐Sc in treating colon cancer.
No takes yet. Share an insight, caveat, or question.
Sakthivel et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: